Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ondoa, Pascale ^a   Shamu, Tinei ^b   Bronze, Michelle ^c   Wellington, Maureen ^b   Boender, Tamara Sonia ^a   Manting, Corry ^a   Steegen, Kim ^c   Luethy, Rudi ^b   Rinke De Wit, Tobias ^a  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b Newlands Clinic   (Zimbabwe)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; HEMOGLOBIN; VIRUS RNA; DIAGNOSTIC KIT; GAG PROTEIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BIOLOGICAL MONITORING; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; FALSE NEGATIVE RESULT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PLASMA; VIROLOGICAL FAILURE ASSAY; VIROLOGY; VIRUS EXAMINATION; VIRUS LOAD; ZIMBABWE; BLOOD; DIAGNOSTIC KIT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; PROCEDURES;

DRIED BLOOD SPOT TESTING; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; REAGENT KITS, DIAGNOSTIC; SPECIMEN HANDLING; VIRAL LOAD; VIROLOGY; ZIMBABWE;

EID: 84904108610     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/102598     Document Type: Article

References (43)

1. WHO, Global Update on HIV Treatment 2013: Results, Impact and Opportunities 2013 Geneva, Switzerland World Health Organization
2. United Nations General Assembly. Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS-United Nations General Assembly Resolution 65/277, New York, NY, USA, United Nations, 2011
3. WHO, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. RecommendAtions for a Public Health Approach
4. WHO, The Strategic Use of Antiretrovirals to Help End the HIV Epidemic Geneva, Switzerland World Health Organization. 2012, http://apps.who.int/iris/ bitstream/10665/75184/1/9789241503921-eng.pdf
5. Sigaloff K. C. E., Hamers R. L., Wallis C. L., Kityo C., Siwale M., Ive P., Botes M. E., Mandaliya K., Wellington M., Osibogun A., Stevens W. S., Van Vugt M., Rinke De Wit T. F., Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. Journal of Acquired Immune Deficiency Syndromes 2011 58 1 23 31 2-s2.0-80155174927 10.1097/QAI.0b013e318227fc34
6. Sigaloff K. C. E., Ramatsebe T., Viana R., de Wit T. F. R., Wallis C. L., Stevens W. S., Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Research and Human Retroviruses 2012 28 2 171 175 2-s2.0-84858043161 10.1089/aid.2011.0136
7. Haubrich R. H., Currier J. S., Forthal D. N., Beall G., Kemper C. A., Johnson D., Dubé M. P., Hwang J., Leedom J. M., Tilles J., McCutchan J. A., A randomized study of the utility of human immunodefidency virus RNA measurement for the management of antiretroviral therapy. Clinical Infectious Diseases 2001 33 7 1060 1068 2-s2.0-0035478394 10.1086/322636 (Pubitemid 32907111)
8. Furrer H., Is it safe to discontinue primary pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed hiv infection and a CD4 cell count <200 cells/ L. Clinical Infectious Diseases 2010 51 5 611 619 2-s2.0-77955836995 10.1086/655761
9. + T-lymphocyte count monitoring necessary for persons with counts ≥300 cells/ L and HIV-1 suppression? Clinical Infectious Diseases 2013 56 9 1340 1343 2-s2.0-84875971238 10.1093/cid/cit004
10. Loutfy M. R., Wu W., Letchumanan M., Bondy L., Antoniou T., Margolese S., Zhang Y., Rueda S., McGee F., Peck R., Binder L., Allard P., Rourke S. B., Rochon P. A., Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS ONE 2013 8 2 2-s2.0-84873898971 10.1371/journal.pone.0055747 e55747
11. Havlir D. V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A. C., Hirsch M. S., Ignacio C., Condra J., Günthard H. F., Richman D. D., Wong J. K., Prevalence and predictive value of intermittent viremia with combination HIV therapy. Journal of the American Medical Association 2001 286 2 171 179 2-s2.0-0034943570 (Pubitemid 32640848)
12. Stevens W. S., Scott L. E., Crowe S. M., Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. The Journal of infectious diseases 2010 201 S16 S26 2-s2.0-77950952587 10.1086/650392
13. Coetzee L. M., Tay S. S., Lawrie D., Janossy G., Glencross D. K., From research tool to routine test: CD38 monitoring in HIV patients. Cytometry B-Clinical Cytometry 2009 76 6 375 384 2-s2.0-75149117396 10.1002/cyto.b.20478
14. Glencross D. K., Janossy G., Coetzee L. M., Lawrie D., Scott L. E., Sanne I., McIntyre J. A., Stevens W., CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: Findings from the first year of the CIPRA-SA cohort. Cytometry B-Clinical Cytometry 2008 74 supplement 1 S131 S140 2-s2.0-42449117109 10.1002/cyto.b.20391 (Pubitemid 351569281)
15. Schüpbach J., Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Reviews 2002 4 2 83 92 2-s2.0-0035988452 (Pubitemid 34808783)
16. Fiscus S. A., HIV-1 viral load assays for resource-limited settings: Authors' reply [5]. PLoS Medicine 2006 3 12 2461 2-s2.0-33845883275 10.1371/journal.pmed.0030550 (Pubitemid 46026465)
17. Greengrass V. L., Turnbull S. P., Hocking J., Dunne A. L., Tachedjian G., Corrigan G. E., Crowe S. M., Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. Current HIV Research 2005 3 2 183 190 2-s2.0-18144426437 10.2174/1570162053506955 (Pubitemid 40614122)
18. Seyoum E., Wolday D., Girma M., Malmsten A., Meselle T., Gronowitz J. S., Britton S., Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-cell count. Journal of Medical Virology 2006 78 2 161 168 2-s2.0-31144438356 10.1002/jmv.20523 (Pubitemid 43132559)
19. Greengrass V. L., Plate M. M., Steele P. M., Denholm J. T., Cherry C. L., Morris L. M., Hearps A., Crowe S. M., Evaluation of the cavidi exaVir load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring. Journal of Clinical Microbiology 2009 47 9 3011 3013 2-s2.0-69949095998 10.1128/JCM.00805-09
20. Rouet F., Ekouevi D. K., Chaix M. L., Burgard M., Inwoley A., Tony T. D., Danel C., Anglaret X., Leroy V., Msellati P., Dabis F., Rouzioux C., Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. Journal of Clinical Microbiology 2005 43 6 2709 2717 2-s2.0-20444489194 10.1128/JCM.43.6.2709-2717. 2005 (Pubitemid 40827943)
21. Rouet F., Chaix M. L., Nerrienet E., Ngo-Giang-Huong N., Plantier J.-C., Burgard M., Peeters M., Damond F., Ekouevi D. K., Msellati P., Ferradini L., Rukobo S., Maréchal V., Schvachsa N., Wakrim L., Rafalimanana C., Rakotoambinina B., Viard J.-P., Seigneurin J.-M., Rouzioux C., Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: Usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. Journal of Acquired Immune Deficiency Syndromes 2007 45 4 380 388 2-s2.0-34447324962 10.1097/QAI.0b013e3180640cf5 (Pubitemid 47057665)
22. Rouet F., Foulongne V., Viljoen J., Steegen K., Becquart P., Valéa D., Danaviah S., Segondy M., Verhofstede C., Van de Perre P., Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 Monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: The Kesho Bora preparatory study. Journal of Virological Methods 2010 163 2 253 257 2-s2.0-73249148437 10.1016/j.jviromet.2009.10.005
23. Bronze M., Aitken S., Wallis C., Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. Journal of Virological Methods 2013 194 300 307
24. Aitken S. C., Kliphuis A., Bronze M., Wallis C. L., Kityo C., Balinda S., Stevens W., Spieker N., De Oliveira T., Rinke De Wit T. F., Schuurman R., Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots. Journal of Clinical Microbiology 2013 51 6 1899 1905 2-s2.0-84878516947 10.1128/JCM.03305-12
25. Schüpbach J., Tomasik Z., Knuchel M., Opravil M., Günthard H. F., Nadal D., Böni J., Aebi C., Battegay M., Bucher H., Bürgisser P., Cattacin S., Cavassini M., Cheseaux J.-J., Drack G., Dubs R., Egger M., Elzi L., Erb P., Fischer M., Flepp M., Fontana A., Francioli P., Furrer H. J., Gayet-Ageron A., Gerber S., Gorgievski M., Hirschel B., Hösl I., Hüsler M., Kaiser L., Kahlert C., Keiser O., Karrer U., Kind C., Klimkait T., Ledergerber B., Martinez B., Müller N., Paccaud F., Pantaleo G., Perrin L., Piffaretti J.-C., Rickenbach M., Rudin C., Schmid P., Schultze D., Schüpbach J., Speck R., Taffé P., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Wechsler A., Wunder D., Wyler C.-A., Yerly S., Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART. Journal of Medical Virology 2006 78 8 1003 1010 2-s2.0-33745726980 10.1002/jmv.20655
26. Hamers R. L., Oyomopito R., Kityo C., Phanuphak P., Siwale M., Sungkanuparph S., Conradie F., Kumarasamy N., Botes M. E., Sirisanthana T., Abdallah S., Li P. C. K., Ngorima N., Kantipong P., Osibogun A., Lee C. K. C., Stevens W. S., Kamarulzaman A., Derdelinckx I., Chen Y.-M. A., Schuurman R., van vugt M., Rinke de wit T. F., Njovu C., Labib M., Menke J., Sanne I., Wallis C. L., Hardman M., Wellington M., Luthy R., Mandaliya K., Jao I., Dolan M., Namayanja G., Nakatudde L., Kiconco M., Abwola M., Mugyenyi P., Ndembiz N., Kaleebu P., Akanmu S., Wensing A. M., Sigaloff K., Straatsma E., Lee M. P., Wong K. H., Saghayam S., Pujari S., Joshi K., Merati T. P., Yuliana F., Low L. L., Ong L. Y., Mustafa M., Nordin N., Ditangco R., Bantique R. O., Wong W. W., Yang Y. W., Sirivichayakul S., Piyavong B., Praparattanapan J., Kambua P., Choi J. Y., Han S. H., Ratanasuwan W., Sriondee R., Kantor R., Sohn A. H., Messerschmidt L., Singtoroj T., Cooper D. A., Law M. G., Jiamsakul A., Zhou J., Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. International Journal of Epidemiology 2012 41 1 43 54 2-s2.0-84863383426 10.1093/ije/dyq192 dyq192
27. The AIDS and TB unit, Ministry of Health and Children Welfare. Guidelines for antiretroviral therapy in Zimbabwe. National Drug and Therapeutic Policy Advisory Committee (NDTPAC), 2010
28. Hamers R. L., Straatsma E., Kityo C., Wallis C. L., Stevens W. S., Sigaloff K. C. E., Siwale M., Conradie F., Botes M. E., Mandaliya K., Wellington M., Osibogun A., Van Vugt M., De Wit T. F. R., Building capacity for the assessment of HIV drug resistance: experiences from the pharmaccess African studies to evaluate resistance network. Clinical Infectious Diseases 2012 54 4 S261 S265 2-s2.0-84860360727 10.1093/cid/cir995
29. Hamers R. L., Smit P. W., Stevens W., Schuurman R., Rinke de Wit T. F., Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antiviral Therapy 2009 14 5 619 629 2-s2.0-69849095336
30. Dachraoui R., Depatureaux A., Chakroun M., Fodha I., Letaief A., Trabelsi A., Simon F., Plantier J.-C., Monitoring of HIV-1 resistance in Tunisia (North Africa) with a dried plasma spot strategy. Journal of Acquired Immune Deficiency Syndromes 2008 47 4 522 525 2-s2.0-40549121924 10.1097/QAI.0b013e318166498a (Pubitemid 351366953)
31. Amellal B., Katlama C., Calvez V., Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification. HIV Medicine 2007 8 6 396 400 2-s2.0-34547468156 10.1111/j.1468-1293.2007.00484.x (Pubitemid 47163272)
32. Prado J. G., Shintani A., Bofill M., Clotet B., Ruiz L., Martinez-Picado J., Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of HIV-1 RNA in patients with chronic HIV infection during structured treatment interruptions. Journal of Clinical Microbiology 2004 42 4 1620 1625 2-s2.0-4544243547 10.1128/JCM.42.4.1620-1625.2004 (Pubitemid 38500806)
33. Bonard D., Rouet F., Toni T. A., Minga A., Huet C., Ekouévi D. K., Dabis F., Salamon R., Rouzioux C., Field Evaluation of an Improved Assay Using a Heat-Dissociated p24 Antigen for Adults Mainly Infected With HIV-1 CRF02-AG Strains in Côte d'Ivoire, West Africa. Journal of Acquired Immune Deficiency Syndromes 2003 34 3 267 273 2-s2.0-0242496510 10.1097/00126334- 200311010-00002 (Pubitemid 37377359)
34. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D., HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996 271 5255 1582 1586 2-s2.0-0029967721 (Pubitemid 26097216)
35. Rouet F., Rouzioux C., The measurement of HIV-1 viral load in resource-limited settings: How and where? Clinical Laboratory 2007 53 3-4 135 148 2-s2.0-34247514336 (Pubitemid 46656568)
36. Erikstrup C., Kallestrup P., Zinyama-Gutsire R. B. L., Gomo E., Lüneborg-Nielsen M., Gerstoft J., Schüpbach J., Ullum H., Katzenstein T. L., P24 as a predictor of mortality in a cohort of HIV-1-infected adults in Rural Africa. Journal of Acquired Immune Deficiency Syndromes 2008 48 3 345 349 2-s2.0-47049101207 10.1097/QAI.0b013e31817dc3d1
37. + T-cell changes between consecutive visits. Journal of Acquired Immune Deficiency Syndromes 2006 41 5 557 562 2-s2.0-33646800547 10.1097/01.qai.0000209824.77784.2c
38. 2014, http://apps.who.int/medicinedocs/fr/d/Js4889f/12.html
39. Hamers R. L., Wallis C. L., Kityo C., Siwale M., Mandaliya K., Conradie F., Botes M. E., Wellington M., Osibogun A., Sigaloff K. C. E., Nankya I., Schuurman R., Wit F. W., Stevens W. S., van Vugt M., de Wit T. F. R., HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. The Lancet Infectious Diseases 2011 11 10 750 759 2-s2.0-80053293363 10.1016/S1473- 3099(11)70149-9
40. Bennett D. E., Bertagnolio S., Sutherland D., Gilks C. F., The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy 2008 13 supplement 2 1 13 2-s2.0-47249109877 (Pubitemid 352019085)
41. WHO, HIV Drug Resistance Report 2012 2012 Geneva, Switzerland World Health Organization
42. Hamers R. L., Sawyer A. W., Tuohy M., Stevens W. S., de Wit T. F. R., Hill A. M., Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012 26 13 1663 1672 2-s2.0-84865460130 10.1097/QAD.0b013e3283560678
43. Sawe F. K., Mclntyre J. A., Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes. Clinical Infectious Diseases 2009 49 3 463 465 2-s2.0-67651111659 10.1086/600397